Residency · Residency · Respirology

Severe Asthma Phenotyping and Biologics

Definition of Severe Asthma

GINA/ERS/ATS Criteria

Severe asthma is defined as asthma that requires GINA Step 4 or Step 5 therapy, specifically medium- to high-dose ICS-LABA with or without additional controllers, to maintain control, or asthma that remains uncontrolled despite this level of therapy. Before a patient can be appropriately labeled as having severe asthma, a systematic evaluation must confirm the diagnosis of asthma itself, optimize medication adherence, ensure correct inhaler technique, treat comorbidities, and eliminate ongoing environmental or occupational exposures. This distinction is critical because severe asthma represents only 5-10% of all asthma patients, yet it is responsible for more than 50% of all asthma-related healthcare costs, including emergency department visits, hospitalizations, and lost productivity. The systematic assessment should include a review of inhaler technique with demonstration by the patient, adherence verification using prescription refill data or, where available, the FeNO suppression test, comprehensive trigger assessment, and structured comorbidity screening.

Distinguishing "Difficult-to-Treat" from "Severe"

The distinction between difficult-to-treat and truly severe asthma is clinically fundamental and directly impacts management decisions. Difficult-to-treat asthma refers to uncontrolled disease attributable to modifiable factors such as poor inhaler technique, medication non-adherence, ongoing tobacco or occupational exposure, or untreated comorbidities including chronic rhinosinusitis, GERD, obesity, or obstructive sleep apnea. These factors may account for up to 50% of patients initially referred for severe asthma management. Severe asthma is reserved for patients whose disease remains truly refractory after optimization of all modifiable factors. Adherence assessment deserves particular attention: electronic inhaler monitoring devices provide objective data on the frequency and timing of medication use, while the FeNO suppression test exploits the predictable reduction in FeNO that follows observed ICS administration in previously non-adherent patients, serving as a practical tool to unmask non-adherence.

Phenotyping and Endotyping

T2-High Asthma

T2-high asthma is defined by the presence of eosinophilic inflammation, allergen-driven IgE pathways, or both, and constitutes the majority of severe asthma cases. Biomarker thresholds supporting this classification include blood eosinophils at or above 150-300 cells per microliter, FeNO at or above 20-25 ppb, sputum eosinophils at or above 3%, and elevated total or specific IgE. Within the T2-high category, several distinct subtypes are recognized. Early-onset allergic asthma typically begins in childhood, is associated with atopy, allergic rhinitis, and atopic dermatitis, is mediated by IgE, and often responds to anti-IgE therapy. Late-onset eosinophilic asthma emerges in adulthood, is frequently non-atopic, and is often accompanied by nasal polyposis. Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad, comprises the combination of asthma, nasal polyposis, and NSAID sensitivity, and is driven by overproduction of cysteinyl leukotrienes. AERD accounts for 15-30% of adults with severe asthma.

T2-Low Asthma

T2-low asthma encompasses neutrophilic and paucigranulocytic inflammatory patterns, driven by distinct mediators including IL-17, IL-8, oxidative stress, and neutrophil extracellular traps. This endotype is associated with obesity, current or former smoking, occupational exposures, and older age. Patients with T2-low asthma characteristically respond poorly to inhaled corticosteroids, which presents a significant therapeutic challenge given the limited biologic options available for this group. Tezepelumab, the anti-TSLP biologic, shows some benefit across T2-low subgroups, representing the most promising biologic option. Chronic macrolide therapy with azithromycin 500 mg three times weekly has demonstrated efficacy in reducing exacerbations in both eosinophilic and non-eosinophilic severe asthma, as shown in the AMAZES trial, offering a pharmacological option for the T2-low population.

Overlap Phenotypes

Several overlap phenotypes add complexity to the clinical picture. Mixed granulocytic asthma, featuring both eosinophilic and neutrophilic inflammation, may require a combined therapeutic approach. The obesity-asthma phenotype involves both mechanical factors (reduced lung volumes, airway closure) and distinct inflammatory pathways, with weight loss of 5-10% consistently improving outcomes. Fungal-sensitized severe asthma, characterized by sensitization to Aspergillus, Alternaria, or Cladosporium, should prompt consideration of antifungal therapy, as explored in the FAST and MFAT trials.

<image>A comprehensive phenotyping algorithm for severe asthma evaluation. Begin with confirmed severe asthma diagnosis (after excluding difficult-to-treat). Branch into T2-high and T2-low pathways based on biomarkers (blood eosinophils, FeNO, IgE, sputum analysis). Under T2-high, further subdivide into: allergic (high IgE + specific sensitization), eosinophilic (high eosinophils +/- FeNO), and overlap. Under T2-low, show neutrophilic and paucigranulocytic arms. For each phenotype, list the recommended biologic options with their targets: omalizumab (IgE), mepolizumab/reslizumab/benralizumab (IL-5/IL-5R), dupilumab (IL-4Ra), tezepelumab (TSLP). Use color coding: orange for T2-high, blue for T2-low, with biomarker thresholds clearly labeled at decision points.</image>

Biologic Therapies

Anti-IgE: Omalizumab

Omalizumab is a humanized monoclonal antibody that binds free circulating IgE, preventing its interaction with the high-affinity IgE receptor (FceRI) on mast cells and basophils, thereby inhibiting the allergic cascade at its initiation. Eligibility requires confirmed allergic sensitization demonstrated by skin prick testing or specific IgE measurement, with a total IgE between 30 and 1500 IU/mL. Dosing is administered by subcutaneous injection every 2 to 4 weeks and is calculated based on both body weight and baseline IgE level using a standardized dosing table. The INNOVATE trial demonstrated a 25% reduction in severe exacerbations, while the EXTRA trial showed a 50% reduction in the high-biomarker subgroup. The onset of clinical benefit typically requires 12-16 weeks, and treatment response should be formally assessed at 4 months. Anaphylaxis is a recognized but uncommon complication, occurring in 0.1-0.2% of patients, necessitating observation for 30 minutes after the first three injections and provision of an epinephrine auto-injector prescription.

Anti-IL-5/IL-5R Pathway

The anti-IL-5 pathway represents a cornerstone of biologic therapy for eosinophilic severe asthma, with three approved agents targeting different components of the pathway. Mepolizumab, an anti-IL-5 monoclonal antibody administered at 100 mg subcutaneously every 4 weeks, was validated by the MENSA trial, which demonstrated a 53% reduction in exacerbations among patients with blood eosinophils at or above 150 at screening or at or above 300 in the preceding year. The MUSCA trial confirmed improvements in quality of life, and the SIRIUS trial demonstrated a 50% median reduction in oral corticosteroid dose. Reslizumab, also targeting IL-5, is the only intravenous biologic for asthma, dosed at 3 mg/kg every 4 weeks, and demonstrated a 54% exacerbation reduction in patients with blood eosinophils at or above 400 in Phase 3 trials. Its intravenous route limits practical adoption in many settings. Benralizumab targets the IL-5 receptor alpha subunit on eosinophils, producing near-complete eosinophil depletion through antibody-dependent cell-mediated cytotoxicity (ADCC), a mechanism distinct from simple cytokine neutralization. Dosed at 30 mg subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, it was validated in the SIROCCO and CALIMA trials (51% exacerbation reduction) and the ZONDA trial (75% median OCS reduction). Benralizumab produces the fastest onset of eosinophil reduction among the anti-IL-5 agents and may be preferred when rapid eosinophil depletion is clinically needed.

Anti-IL-4 Receptor Alpha: Dupilumab

Dupilumab is a fully human monoclonal antibody that blocks the IL-4 receptor alpha subunit, which is shared by both IL-4 and IL-13, thereby simultaneously inhibiting signaling through both cytokine pathways. This dual blockade addresses a broad spectrum of T2 inflammatory effects. Dosing consists of a loading dose (400 mg or 600 mg) followed by 200 mg or 300 mg subcutaneously every 2 weeks. The pivotal LIBERTY ASTHMA QUEST trial demonstrated a 48% overall exacerbation reduction, rising to 70% in the subgroup with blood eosinophils at or above 300, while the VENTURE trial showed a 70% reduction in oral corticosteroid dose. Dupilumab has the broadest biomarker eligibility among the asthma biologics, with clinical benefit observed in patients with eosinophils at or above 150 or FeNO at or above 25 ppb. Beyond asthma, dupilumab holds regulatory approval for atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, COPD with T2 inflammation, and prurigo nodularis, making it the preferred choice for patients with multiple T2 comorbidities. A unique side effect is transient blood eosinophilia, which occurs because blockade of IL-4 receptor alpha inhibits eosinophil migration from the bloodstream into tissues. This is usually benign and self-limited but should be monitored for rare hypereosinophilic complications.

Anti-TSLP: Tezepelumab

Tezepelumab represents a fundamentally different approach to asthma biologics by targeting thymic stromal lymphopoietin (TSLP), an epithelial alarmin released at the very top of the inflammatory cascade in response to airway epithelial damage. By blocking this upstream mediator, tezepelumab has the potential to attenuate both T2-high and T2-low inflammatory pathways. Dosed at 210 mg subcutaneously every 4 weeks, tezepelumab was validated in the Phase 2 PATHWAY trial (71% exacerbation reduction) and the Phase 3 NAVIGATOR trial (56% overall exacerbation reduction), with the notable finding that clinical benefit extended across T2-high and T2-low subgroups. The SOURCE trial, however, did not demonstrate significant oral corticosteroid sparing, representing a negative primary endpoint for that particular outcome. Tezepelumab is the first biologic to show efficacy regardless of baseline T2 biomarker status, offering a potential therapeutic option for T2-low severe asthma. It has received FDA and EMA approval for severe asthma in patients aged 12 and older without phenotype restriction.

<image>A molecular pathway diagram showing the targets of each asthma biologic. Illustrate the T2 inflammatory cascade starting from allergen exposure and epithelial damage. Show epithelial alarmins (TSLP targeted by tezepelumab, IL-25, IL-33) activating dendritic cells and ILC2 cells. Show Th2 cells producing IL-4 and IL-13 (both blocked by dupilumab at IL-4Ra) and IL-5 (blocked by mepolizumab and reslizumab). Show IL-5Ra on eosinophils (blocked by benralizumab). Show IgE pathway from B cells (blocked by omalizumab). Downstream effects: eosinophil recruitment, mucus production, airway remodeling, bronchoconstriction. Use distinct colors for each drug with their molecular targets clearly marked.</image>

Biologic Selection Algorithm

Practical Considerations

Biologic selection requires careful integration of phenotypic data, comorbidity burden, and practical considerations. For patients with an allergic phenotype featuring elevated IgE and concurrent eosinophilia, both omalizumab and dupilumab are options, with dupilumab preferred when eosinophils exceed 300 or concomitant T2 comorbidities are present. For predominantly eosinophilic non-allergic asthma, mepolizumab, benralizumab, or dupilumab are appropriate choices. When oral corticosteroid dependence is the primary concern, benralizumab (ZONDA) and dupilumab (VENTURE) offer the strongest OCS-sparing evidence. For T2-low or biomarker-indeterminate severe asthma, tezepelumab is the only biologic with supporting evidence. Comorbid chronic rhinosinusitis with nasal polyps favors dupilumab, mepolizumab, or omalizumab, all of which have demonstrated benefit in this population. Comorbid atopic dermatitis strongly favors dupilumab given its dual indication. When rapid eosinophil depletion is needed, such as in cases where EGPA is a diagnostic concern, benralizumab is preferred.

Response Assessment

Every biologic trial should be assessed after a minimum of 4 months (omalizumab may require 4 to 6 months). The assessment encompasses exacerbation frequency, oral corticosteroid requirements, symptom control as measured by ACT or ACQ, lung function, and quality of life. Superresponders, defined as patients achieving no exacerbations, complete OCS withdrawal, and normalized lung function, may represent up to 30% of well-selected patients. For non-responders, switching to an alternative biologic targeting a different pathway is appropriate, with reassessment of the underlying phenotype to guide the selection.

Biologic Switching

No mandatory washout period exists between biologics, and some experts advocate an overlap period to prevent loss of disease control during the transition. When switching, it is generally preferable to target a different mechanism of action rather than switching within the same pathway. Real-world switching data suggest that approximately 50-60% of patients who fail one biologic will respond to an alternative agent.

Adjunctive Therapies in Severe Asthma

Bronchial Thermoplasty

Bronchial thermoplasty is a bronchoscopic procedure that delivers radiofrequency energy to the airway wall, targeting airway smooth muscle reduction. The AIR2 trial demonstrated a modest reduction in severe exacerbations and improvement in quality of life, although the effect size has been considered controversial and difficult to separate from placebo response. The BT10+ study reported durable effects at 10 years in selected patients. Bronchial thermoplasty is typically reserved for patients with severe asthma refractory to biologic therapy, has limited availability, and is performed over three bronchoscopy sessions spaced several weeks apart.

Chronic Macrolide Therapy

Azithromycin at 500 mg three times weekly has demonstrated significant efficacy as an adjunctive therapy for severe asthma. The AMAZES trial showed a 41% reduction in exacerbations across both eosinophilic and non-eosinophilic phenotypes, suggesting that the benefits derive from anti-inflammatory and immunomodulatory properties rather than antimicrobial effects. The risks include QTc prolongation, necessitating a baseline ECG, hearing impairment with long-term use, and the important public health concern of promoting antimicrobial resistance. Chronic macrolide therapy should be considered in severe asthma refractory to biologics, with particular relevance for the T2-low neutrophilic phenotype.

Oral Corticosteroid Minimization

Chronic oral corticosteroid use carries dose-dependent and cumulative toxicity affecting virtually every organ system, including osteoporosis, adrenal suppression, diabetes, cataracts, weight gain, and immunosuppression. Even maintenance doses as low as 5 mg of prednisone daily carry significant risk when administered chronically. All severe asthma patients on maintenance oral corticosteroids should be assessed for biologic initiation with explicit OCS-sparing intent. During OCS weaning, monitoring for adrenal insufficiency is essential, and tapering should proceed gradually at a rate of 1 to 2.5 mg of prednisone per month to allow hypothalamic-pituitary-adrenal axis recovery.

<image>A clinical decision support flowchart for biologic selection in severe asthma. Start with confirmed severe asthma diagnosis. First decision node: T2-high vs. T2-low based on biomarkers (blood eos >= 150, FeNO >= 20, IgE elevated). For T2-high: branch into allergic (elevated specific IgE) and eosinophilic (blood eos >= 300) paths. Show eligible biologics at each node with key differentiating factors: comorbid CRSwNP favors dupilumab/mepolizumab, comorbid atopic dermatitis favors dupilumab, OCS-dependent favors benralizumab/dupilumab, need for rapid eosinophil depletion favors benralizumab. For T2-low: tezepelumab as primary option, azithromycin as adjunct. Include response assessment at 4 months with switch strategy if inadequate response.</image>

Key Clinical Pearls

• Up to 50% of "severe" asthma is actually difficult-to-treat due to poor adherence, incorrect inhaler technique, or untreated comorbidities - systematic assessment is mandatory before biologic initiation
• Dupilumab has the broadest biomarker eligibility and multisystem T2 disease coverage (asthma + AD + CRSwNP + EoE); it may cause transient eosinophilia that is usually clinically insignificant
• Tezepelumab is the only biologic with demonstrated efficacy regardless of T2 biomarker status, making it a potential option for T2-low severe asthma
• Benralizumab causes near-complete eosinophil depletion via ADCC and has the most robust OCS-sparing data alongside dupilumab
• SABA overuse (>= 3 canisters/year) in severe asthma is associated with increased mortality risk and should trigger urgent management review

References

1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373.
2. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384(19):1800-1809. (NAVIGATOR)
3. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-2496. (LIBERTY ASTHMA QUEST)
4. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376(25):2448-2458. (ZONDA)
5. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659-668.

Read this lecture as Markdown